.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
Novartis
UBS
McKinsey
Johnson and Johnson
McKesson
Harvard Business School
Healthtrust
Fish and Richardson
US Department of Justice

Generated: September 26, 2017

DrugPatentWatch Database Preview

Dexamethasone - Generic Drug Details

« Back to Dashboard

What are the generic sources for dexamethasone and what is the scope of dexamethasone patent protection?

Dexamethasone
is the generic ingredient in thirty-one branded drugs marketed by ECR, Phoenix Labs Ny, West-ward Pharms Int, Sun Pharm Inds, Roxane, Allergan, Watson Labs, Pvt Form, Novartis Pharms Corp, Whiteworth Town Plsn, Merck, Upsher Smith, Xspire Pharma, Par Pharm, Sti Pharma Llc, Wockhardt Eu Operatn, Larken Labs Inc, Organon Usa Inc, Impax Labs, Vintage Pharms, Solvay, Lyne, Allergan Herbert, Alpharma Us Pharms, Idt Australia Ltd, Watson Labs Teva, Mylan Labs Ltd, Ucb Inc, Fresenius Kabi Usa, Intl Medication, Teva Parenteral, Pharmafair, Luitpold, Wyeth Ayerst, Cent Pharms, Alcon, Abraxis Pharm, Bel Mar, Akorn, Dell Labs, Lyphomed, Bausch And Lomb, Sola Barnes Hind, Sandoz Inc, Aurobindo Pharma Ltd, Alcon Pharms Ltd, Perrigo Co Tennessee, and Novartis, and is included in one hundred and twenty-four NDAs. There are seventeen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Dexamethasone has one hundred and twenty-five patent family members in twenty-six countries.

There are thirty-nine drug master file entries for dexamethasone. Thirty-seven suppliers are listed for this compound.

Summary for Generic Name: dexamethasone

Tradenames:31
Patents:17
Applicants:48
NDAs:124
Drug Master File Entries: see list39
Suppliers / Packagers: see list37
Bulk Api Vendors: see list76
Clinical Trials: see list1,990
Therapeutic Class:Ophthalmic Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:dexamethasone at DailyMed

Pharmacology for Ingredient: dexamethasone

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
West-ward Pharms Int
DEXAMETHASONE
dexamethasone
TABLET;ORAL084612-001Approved Prior to Jan 1, 1982BPRXNoNo► Subscribe► Subscribe► Subscribe
Novartis Pharms Corp
TOBRADEX
dexamethasone; tobramycin
OINTMENT;OPHTHALMIC050616-001Sep 28, 1988RXYesYes► Subscribe► Subscribe► Subscribe
Idt Australia Ltd
DEXAMETHASONE
dexamethasone
TABLET;ORAL080399-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Par Pharm
DEXAMETHASONE
dexamethasone
TABLET;ORAL088238-001Apr 28, 1983BPRXNoNo► Subscribe► Subscribe► Subscribe
Sun Pharm Inds
DEXAMETHASONE
dexamethasone
TABLET;ORAL084084-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Merck
DECADRON
dexamethasone
ELIXIR;ORAL012376-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Watson Labs Teva
DEXAMETHASONE ACETATE
dexamethasone acetate
INJECTABLE;INJECTION087711-001May 24, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Par Pharm
DEXAMETHASONE
dexamethasone
TABLET;ORAL088149-001Apr 28, 1983DISCNNoNo► Subscribe► Subscribe► Subscribe
West-ward Pharms Int
DEXAMETHASONE SODIUM PHOSPHATE
dexamethasone sodium phosphate
INJECTABLE;INJECTION087702-001Sep 7, 1982APRXNoYes► Subscribe► Subscribe► Subscribe
Watson Labs
DEXAMETHASONE
dexamethasone
TABLET;ORAL085458-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: dexamethasone

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,242,099Implants and methods for treating inflammation-mediated conditions of the eye► Subscribe
8,048,445Ocular implant made by a double extrusion process► Subscribe
8,828,446Method for reducing transplant rejection in the eye and intraocular implants for use therefor► Subscribe
8,071,120Methods for treating neovascularization and intravitreal implants► Subscribe
7,090,681Methods and apparatus for delivery of ocular implants► Subscribe
7,753,916Methods and apparatus for delivery of ocular implants► Subscribe
6,699,493 Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor► Subscribe
7,468,065Apparatus for delivery of ocular implants► Subscribe
8,778,381Ocular implant made by a double extrusion process► Subscribe
7,625,582Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: dexamethasone

Country Document Number Estimated Expiration
Australia7316601► Subscribe
Slovenia1776091► Subscribe
Hong Kong1082902► Subscribe
European Patent Office1339438► Subscribe
MexicoPA05002841► Subscribe
Poland376478► Subscribe
New Zealand540451► Subscribe
European Patent Office1581193► Subscribe
Israel180865► Subscribe
European Patent Office1917957► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: DEXAMETHASONE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00552Netherlands► SubscribePRODUCT NAME: VOOR GEBRUIK IN EEN WERKWIJZE VOOR DE BEHANDELING VAN MACULAIR OEDEEM; REG. NO/DATE: EU/1/10/638/001 20100727
2012000081Germany► SubscribePRODUCT NAME: DEXAMETHASON; REGISTRATION NO/DATE: EU/1/10/638/001 20100727
C0012France► SubscribePRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808
C/GB12/058United Kingdom► SubscribePRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
Queensland Health
McKesson
Dow
Johnson and Johnson
Healthtrust
Medtronic
Cerilliant
Federal Trade Commission
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot